BPI-572270 / Betta Pharma - LARVOL DELTA

BPI-572270: An orally bioavailable and highly potent RAS (On) multi tri-complex inhibitor (AACR 2025) - "Safety evaluations in repeated-dose studies in rats and beagle dogs indicate a promising safety profile, reinforcing its potential for further clinical development. In conclusion, BPI-572270 emerges as a highly potent, orally bioavailable RAS(On)multi inhibitor, with favorable efficacy, pharmacokinetics, and safety profiles in pre-clinical studies."

Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • HRAS • KRAS • NRAS